The Public Employees Retirement Association of Colorado decides to keep it stake in Celgene Corp. (CELG) to the level of $16,208,000

The Public Employees Retirement Association of Colorado decides to keep it stake in Celgene Corp. (CELG) to the level of $16,208,000

Public Employees Retirement Association of Colorado cut its position in shares of Celgene Corp. (NASDAQ:CELG) by 5.9% during the second quarter, Holdings Channel reports. The firm owned 164,328 shares of the biopharmaceutical company’s stock after selling 10,224 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Celgene Corp. were worth $16,208,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CELG. Jolley Asset Management LLC raised its stake in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 450 shares during the period. Kings Point Capital Management raised its stake in shares of Celgene Corp. by 1.7% in the first quarter. Kings Point Capital Management now owns 1,316 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 22 shares during the period. Integrated Investment Consultants LLC raised its stake in shares of Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 240 shares during the period. Ropes Wealth Advisors LLC raised its stake in shares of Celgene Corp. by 0.9% in the first quarter. Ropes Wealth Advisors LLC now owns 1,477 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 13 shares during the period. Finally, Opera Trading Capital raised its stake in shares of Celgene Corp. by 135.7% in the first quarter. Opera Trading Capital now owns 1,563 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 900 shares during the period. Institutional investors and hedge funds own 77.75% of the company’s stock.

Celgene Corp. (NASDAQ:CELG) traded down 1.38% during mid-day trading on Wednesday, reaching $100.24. The company had a trading volume of 1,856,745 shares. The firm’s 50-day moving average price is $106.71 and its 200-day moving average price is $105.56. The stock has a market cap of $77.70 billion, a PE ratio of 42.37 and a beta of 1.49. Celgene Corp. has a 12 month low of $93.05 and a 12 month high of $128.39.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.05. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. The firm’s quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.23 EPS. Equities research analysts forecast that Celgene Corp. will post $5.71 EPS for the current fiscal year.

A number of equities research analysts have weighed in on CELG shares. Jefferies Group restated a “buy” rating and set a $140.00 price objective on shares of Celgene Corp. in a research note on Wednesday, June 29th. Vetr lowered Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $108.18 price objective for the company. in a research note on Wednesday, June 29th. Canaccord Genuity restated a “buy” rating and set a $156.00 price objective on shares of Celgene Corp. in a research note on Monday, June 27th. JMP Securities restated a “buy” rating and set a $152.00 price objective on shares of Celgene Corp. in a research note on Thursday, June 23rd. Finally, Stifel Nicolaus started coverage on Celgene Corp. in a research note on Thursday, July 14th. They set a “buy” rating and a $138.00 price objective for the company. Three analysts have rated the stock with a hold rating and twenty-five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $137.44.

In other news, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $110.00, for a total value of $11,000,000.00. Following the transaction, the insider now owns 1,022,201 shares of the company’s stock, valued at approximately $112,442,110. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael A. Friedman sold 56,116 shares of the stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $103.66, for a total value of $5,816,984.56. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $5,183,000. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Related posts

Leave a Comment